TL;DR — Creatine and Huntington’s Disease
Huntington’s disease (HD) is a devastating inherited neurodegenerative disorder caused by a mutation in the huntingtin gene. The disease progressively destroys neurons, particularly in the striatum, leading to motor dysfunction, cognitive decline, and psychiatric symptoms. A central feature of HD pathology is severe mitochondrial dysfunction and impaired brain energy metabolism. This energy deficit hypothesis made creatine — the brain’s primary rapid energy buffer — an attractive candidate for neuroprotection. Preclinical studies in HD animal models showed impressive results, with creatine supplementation extending lifespan and reducing neuronal loss. However, the large-scale CREST-E clinical trial in humans did not demonstrate significant slowing of functional decline. Despite these disappointing clinical results, the research has deepened our understanding of brain energy metabolism in neurodegeneration and continues to inform therapeutic development.
The Energy Deficit in Huntington’s Disease
Huntington’s disease involves profound disruption of cellular energy metabolism:
Mitochondrial impairment. The mutant huntingtin protein directly interferes with mitochondrial function, reducing electron transport chain activity, decreasing ATP production, and increasing oxidative stress within neurons.
Striatal vulnerability. The striatum — the brain region most severely affected in HD — has particularly high energy demands. Medium spiny neurons in the striatum are especially susceptible to energy deficits, which may explain their selective vulnerability.
Progressive energy failure. As the disease progresses, the gap between neuronal energy demand and supply widens. This progressive energy failure contributes to excitotoxicity, oxidative damage, and ultimately neuronal death.
Creatine kinase system disruption. Studies have found reduced creatine kinase activity in HD brain tissue, suggesting that the phosphocreatine energy buffering system itself becomes compromised as part of the disease process (RB et al., 2017) .
Preclinical Evidence: Animal Studies
The preclinical evidence for creatine in Huntington’s disease models was remarkably promising:
Transgenic mouse models. In the R6/2 transgenic mouse model of HD, creatine supplementation at 2% of diet extended survival by approximately 17%, reduced brain atrophy, and decreased the formation of huntingtin protein aggregates. These results generated significant excitement in the research community.
Neuroprotective mechanisms. Animal studies revealed multiple mechanisms through which creatine appeared to protect HD neurons: buffering ATP levels during energy crises, reducing oxidative stress markers, stabilizing mitochondrial membrane potential, and inhibiting activation of cell death pathways.
3-Nitropropionic acid models. In chemical models of HD using 3-NP (which mimics HD-like mitochondrial dysfunction), creatine supplementation provided substantial protection against striatal lesions and motor dysfunction.
Dose-response relationships. Higher doses of creatine produced greater neuroprotective effects in animal models, suggesting a dose-dependent relationship that influenced the design of subsequent human trials.
Clinical Trials: The CREST-E Study
The Creatine Safety, Tolerability, and Efficacy in Huntington’s Disease (CREST-E) trial was one of the largest clinical trials conducted in HD:
Study design. CREST-E was a Phase III, multicenter, randomized, double-blind, placebo-controlled trial involving 553 participants across 46 sites in North America and Europe. Participants received creatine at doses up to 40g/day or placebo for up to 48 months.
Primary outcome. The trial measured functional decline using the Total Functional Capacity (TFC) scale. Unfortunately, the study was stopped early for futility — an interim analysis indicated that creatine was unlikely to show benefit even if the trial continued to completion.
Safety findings. Despite the lack of efficacy, CREST-E confirmed that creatine was remarkably well-tolerated even at 40g/day for extended periods. Gastrointestinal side effects were more common in the creatine group but were generally manageable.
Lessons learned. The disconnect between animal and human results highlighted challenges in translating neuroprotection from preclinical models to clinical practice. Factors including disease stage at intervention, dosing relative to brain creatine uptake, and the limitations of the blood-brain barrier in creatine transport may have contributed to the lack of clinical effect (H et al., 2021) .
Why Animal Results Did Not Translate
Several factors may explain the gap between promising preclinical results and the lack of clinical benefit:
Blood-brain barrier limitation. Creatine crosses the blood-brain barrier (BBB) poorly in adults. While animal models may benefit from starting supplementation early (before BBB maturation), adult humans have limited capacity to increase brain creatine through oral supplementation alone.
Disease stage. Human trials enrolled participants who already had manifest HD. By this stage, significant neuronal loss had already occurred. Earlier intervention — potentially decades before symptom onset — might yield different results.
Species differences. Rodent models, while valuable, do not perfectly replicate the complexity of human HD. Differences in brain size, creatine metabolism, and disease progression timelines all affect translatability.
Malaysian Context
While Huntington’s disease is relatively rare in Malaysia compared to Western populations, Malaysian researchers and neurologists contribute to understanding neurodegenerative diseases. Malaysian families affected by HD can access genetic testing and counseling through major medical centres in Kuala Lumpur and Penang. The creatine research in HD, while not yielding a direct treatment, has advanced understanding of brain energy metabolism that benefits broader neurodegenerative disease research relevant to Malaysia’s aging population.
The Path Forward
Despite CREST-E’s negative results, creatine research in HD has not ended:
- Pre-manifest intervention. Some researchers advocate for trials in pre-manifest HD gene carriers, where neuroprotection might be more effective before significant neuronal loss occurs.
- Combination strategies. Creatine combined with other mitochondrial support compounds (CoQ10, alpha-lipoic acid) may provide synergistic neuroprotection.
- Novel delivery methods. Approaches to bypass the BBB, such as creatine esters or nanoparticle delivery, could increase brain creatine levels more effectively.
Key Takeaways
Creatine’s journey in Huntington’s disease research illustrates both the potential and the challenges of translational neuroscience. While the phosphocreatine energy system remains a valid therapeutic target in HD, delivering sufficient creatine to the brain and intervening at the right disease stage remain significant hurdles. For Malaysian families affected by HD, staying informed about ongoing research through reputable sources remains important while following established treatment protocols.